about
Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza virusesInfluenza and respiratory syncytial virus in infants study (IRIS) of hospitalized and non-ill infants aged <1 year in four countries: study design and methodsH7N9 influenza virus neutralizing antibodies that possess few somatic mutationsVaccine-elicited antibody that neutralizes H5N1 influenza and variants binds the receptor site and polymorphic sites.A chemically programmed antibody is a long-lasting and potent inhibitor of influenza neuraminidaseRespiratory syncytial virus regulates human microRNAs by using mechanisms involving beta interferon and NF-κB.Induction of epidermal growth factor receptor expression by Epstein-Barr virus latent membrane protein 1 C-terminal-activating region 1 is mediated by NF-kappaB p50 homodimer/Bcl-3 complexes.The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.Identification of Epstein-Barr virus RK-BARF0-interacting proteins and characterization of expression pattern.Transforming growth factor beta is a major regulator of human neonatal immune responses following respiratory syncytial virus infectionGold nanorod vaccine for respiratory syncytial virus.Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model.Multihospital Outbreak of a Middle East Respiratory Syndrome Coronavirus Deletion Variant, Jordan: A Molecular, Serologic, and Epidemiologic InvestigationAdvances in Emerging and Neglected Infectious Diseases 2018Serologic Follow-up of Middle East Respiratory Syndrome Coronavirus Cases and Contacts-Abu Dhabi, United Arab EmiratesLMP1 signaling and activation of NF-kappaB in LMP1 transgenic miceIsolation and characterization of SARS-CoV-2 from the first US COVID-19 patientAn orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirusValidation of a SARS-CoV-2 spike protein ELISA for use in contact investigations and sero-surveillance
P50
Q27679859-1754ACFD-9AB7-43C6-847F-FDE222CFDDBBQ29248088-9827157A-742E-4AA8-9714-05AA97959FF7Q30385356-A9C52EAA-359F-4179-801D-0A4F55721D79Q35910153-2FAF3E9E-07D4-4A02-ACE8-75989C786C75Q36452689-56DC8E24-F6FB-4104-A01C-408821670FDFQ36486630-9E95A3B6-4224-40DD-94A8-18EEB0BD0BE9Q40078279-0C50394B-76E3-4CD6-AC5E-2D6009A8FE4AQ40151720-9C871D89-75E9-4B57-98D9-BEB69BB4B04CQ40275967-2AF90D83-7D23-4803-9E74-F36DA7ACB4CBQ41231990-7A194AB8-D9D6-40B5-AC4C-E2963540B5DCQ42051308-D6E202A6-DD5F-442F-8D95-D5992C5A8137Q52717887-3F107303-45EC-4500-A72A-793C8D2ED04DQ57193101-43AD223C-7F48-429F-8CD6-DF9F292DA878Q64136666-1665A8E1-31BE-40F3-BD43-24CEE9257CA6Q64137373-8B02B05F-7E20-47AE-A6B2-FBC373836449Q81398990-6FDA71E7-8C68-4999-A164-DA1497EAE74FQ88975963-20698309-0CEB-4EC3-9E56-4ACB92C0F524Q88978122-8C1B9BA8-8B5A-4651-A340-5FF873BE9B01Q95604535-6252CA01-0540-4D5A-9EA5-C14E8A940EA3
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Natalie J Thornburg
@ast
Natalie J Thornburg
@en
Natalie J Thornburg
@es
Natalie J Thornburg
@nl
type
label
Natalie J Thornburg
@ast
Natalie J Thornburg
@en
Natalie J Thornburg
@es
Natalie J Thornburg
@nl
prefLabel
Natalie J Thornburg
@ast
Natalie J Thornburg
@en
Natalie J Thornburg
@es
Natalie J Thornburg
@nl
P106
P1153
6602664202
P21
P31
P496
0000-0003-3523-3616